Annual Accounts Payable
$10.44 M
-$3.04 M-22.54%
June 30, 2024
Summary
- As of February 21, 2025, AYTU annual accounts payable is $10.44 million, with the most recent change of -$3.04 million (-22.54%) on June 30, 2024.
- During the last 3 years, AYTU annual accounts payable has fallen by -$8.81 million (-45.78%).
- AYTU annual accounts payable is now -45.78% below its all-time high of $19.25 million, reached on June 30, 2021.
Performance
AYTU Accounts Payable Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly Accounts Payable
$11.70 M
-$1.81 M-13.42%
December 31, 2024
Summary
- As of February 21, 2025, AYTU quarterly accounts payable is $11.70 million, with the most recent change of -$1.81 million (-13.42%) on December 31, 2024.
- Over the past year, AYTU quarterly accounts payable has increased by +$1.23 million (+11.71%).
- AYTU quarterly accounts payable is now -39.24% below its all-time high of $19.25 million, reached on June 30, 2021.
Performance
AYTU Quarterly Accounts Payable Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Accounts Payable Formula
Accounts Payable = Beginning Accounts Payable + Purchases on Credit − Payments to Suppliers
AYTU Accounts Payable Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1 y1 year | -22.5% | +11.7% |
| 3 y3 years | -45.8% | +11.7% |
| 5 y5 years | +389.3% | +11.7% |
AYTU Accounts Payable Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
|---|---|---|---|---|---|
| 3 y | 3-year | -45.8% | at low | -25.0% | +12.1% |
| 5 y | 5-year | -45.8% | +389.3% | -39.2% | +102.6% |
| alltime | all time | -45.8% | -100.0% | -39.2% | -100.0% |
Aytu BioPharma Accounts Payable History
| Date | Annual | Quarterly |
|---|---|---|
| Dec 2024 | - | $11.70 M(-13.4%) |
| Sep 2024 | - | $13.51 M(+29.4%) |
| Jun 2024 | $10.44 M(-22.5%) | $10.44 M(-0.3%) |
| Mar 2024 | - | $10.47 M(+0.0%) |
| Dec 2023 | - | $10.47 M(-27.6%) |
| Sep 2023 | - | $14.47 M(+7.3%) |
| Jun 2023 | $13.48 M(+22.7%) | $13.48 M(-8.1%) |
| Mar 2023 | - | $14.67 M(+38.7%) |
| Dec 2022 | - | $10.58 M(-27.9%) |
| Sep 2022 | - | $14.67 M(+33.5%) |
| Jun 2022 | $10.99 M(-42.9%) | $10.99 M(-1.3%) |
| Mar 2022 | - | $11.13 M(-28.7%) |
| Dec 2021 | - | $15.60 M(+66.3%) |
| Sep 2021 | - | $9.38 M(-51.3%) |
| Jun 2021 | $19.25 M(+65.4%) | $19.25 M(+16.5%) |
| Mar 2021 | - | $16.53 M(+130.9%) |
| Dec 2020 | - | $7.16 M(+24.0%) |
| Sep 2020 | - | $5.77 M(-50.4%) |
| Jun 2020 | $11.64 M(+445.6%) | $11.64 M(+67.3%) |
| Mar 2020 | - | $6.96 M(-27.5%) |
| Dec 2019 | - | $9.60 M(+264.6%) |
| Sep 2019 | - | $2.63 M(+23.4%) |
| Jun 2019 | $2.13 M(+0.7%) | $2.13 M(+0.1%) |
| Mar 2019 | - | $2.13 M(-10.1%) |
| Dec 2018 | - | $2.37 M(+12.3%) |
| Sep 2018 | - | $2.11 M(-0.4%) |
| Jun 2018 | $2.12 M(-4.5%) | $2.12 M(-33.7%) |
| Mar 2018 | - | $3.20 M(-6.3%) |
| Dec 2017 | - | $3.41 M(+105.6%) |
| Sep 2017 | - | $1.66 M(-25.2%) |
| Jun 2017 | $2.22 M | $2.22 M(+57.6%) |
| Mar 2017 | - | $1.41 M(-42.4%) |
| Dec 2016 | - | $2.45 M(-2.5%) |
| Date | Annual | Quarterly |
|---|---|---|
| Sep 2016 | - | $2.51 M(+8.0%) |
| Jun 2016 | $2.32 M(+94.3%) | $2.32 M(+97.3%) |
| Mar 2016 | - | $1.18 M(+9.4%) |
| Dec 2015 | - | $1.08 M(+0.1%) |
| Sep 2015 | - | $1.08 M(-10.1%) |
| Jun 2015 | $1.20 M(>+9900.0%) | $1.20 M(+118.8%) |
| Mar 2015 | - | $546.30 K(>+9900.0%) |
| Feb 2015 | - | $4300.00(+19.4%) |
| Nov 2014 | - | $3600.00(+1100.0%) |
| Aug 2014 | $300.00(-100.0%) | $300.00(-90.0%) |
| Jun 2014 | $649.50 K(+9451.5%) | - |
| May 2014 | - | $3000.00(-73.0%) |
| Feb 2014 | - | $11.10 K(-13.3%) |
| Nov 2013 | - | $12.80 K(+88.2%) |
| Aug 2013 | $6800.00(+17.2%) | $6800.00(-8.1%) |
| May 2013 | - | $7400.00(-47.1%) |
| Feb 2013 | - | $14.00 K(+16.7%) |
| Nov 2012 | - | $12.00 K(+106.9%) |
| Aug 2012 | $5800.00(+1833.3%) | $5800.00(+41.5%) |
| May 2012 | - | $4100.00(+5.1%) |
| Feb 2012 | - | $3900.00(-29.1%) |
| Nov 2011 | - | $5500.00(+1733.3%) |
| Aug 2011 | $300.00(-40.0%) | $300.00(-66.7%) |
| May 2011 | - | $900.00(>+9900.0%) |
| Feb 2011 | - | $0.00(-100.0%) |
| Nov 2010 | - | $2800.00(+460.0%) |
| Aug 2010 | $500.00(>+9900.0%) | $500.00(>+9900.0%) |
| May 2010 | - | $0.00(-100.0%) |
| Feb 2010 | - | $2900.00(-27.5%) |
| Nov 2009 | - | $4000.00(>+9900.0%) |
| Aug 2009 | $0.00(-100.0%) | $0.00(-100.0%) |
| May 2008 | - | $6300.00(+80.0%) |
| Nov 2007 | - | $3500.00(+105.9%) |
| Aug 2007 | $1700.00 | $1700.00 |
FAQ
- What is Aytu BioPharma annual accounts payable?
- What is the all time high annual accounts payable for Aytu BioPharma?
- What is Aytu BioPharma annual accounts payable year-on-year change?
- What is Aytu BioPharma quarterly accounts payable?
- What is the all time high quarterly accounts payable for Aytu BioPharma?
- What is Aytu BioPharma quarterly accounts payable year-on-year change?
What is Aytu BioPharma annual accounts payable?
The current annual accounts payable of AYTU is $10.44 M
What is the all time high annual accounts payable for Aytu BioPharma?
Aytu BioPharma all-time high annual accounts payable is $19.25 M
What is Aytu BioPharma annual accounts payable year-on-year change?
Over the past year, AYTU annual accounts payable has changed by -$3.04 M (-22.54%)
What is Aytu BioPharma quarterly accounts payable?
The current quarterly accounts payable of AYTU is $11.70 M
What is the all time high quarterly accounts payable for Aytu BioPharma?
Aytu BioPharma all-time high quarterly accounts payable is $19.25 M
What is Aytu BioPharma quarterly accounts payable year-on-year change?
Over the past year, AYTU quarterly accounts payable has changed by +$1.23 M (+11.71%)